Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.
|Videos|April 27, 2015
Sandra Spoelstra on the Challenges of Oral Cancer Medication Adherence
Author(s)Sandra Spoelstra, PhD, RN
Sandra Spoelstra, PhD, RN, Assistant Professor, College of Nursing, Michigan State University, explains some of the reasons why cancer patients don't adhere to their oral medications.
Advertisement
Sandra Spoelstra, PhD, RN, Assistant Professor, College of Nursing, Michigan State University, explains some of the reasons why cancer patients don’t adhere to their oral medications.
Spoelstra says some patients don’t know what their medication is for. Therefore, they don’t understand the need to take it consistently. Other patients will self modulate their oral medication in an effort to manage the side effects from the agent, Spoelstra says.
<<<
Advertisement
Related to this article
Kate Kennedy, MSN, APRN, explains how Vanderbilt-Ingram's award-winning APP clinic moved bispecific step-up dosing out of the hospital.
As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.
Daraxonrasib, tarlatamab, an mRNA melanoma therapy and ivonescimab led ESMO 2026. Tell us which findings you can act on now.
Suzanne E. Barron, CRNP, explains how education, premedication, and pharmacy coordination streamline intravesical gene therapy treatment days.
At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.
Dana-Farber nurse practitioners reflect on cross-country networking, resource gaps, and ADC education needs after JADPRO Live 2026.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
2
Inside an APP-Led Outpatient Clinic for Bispecific Step-Up Dosing
3
AYA Needs Navigation Trial Meets Most Fidelity Targets at Interim Look
4
October 2026 FDA Approvals: 7 Cancer Updates for Oncology Nurses
5